Lin BioScience, Inc.

Lin BioScience, Inc. is a clinical-stage biotechnology company headquartered in Taipei, Taiwan, focused on the research and development of innovative pharmaceuticals that address diseases with significant unmet medical needs. Founded in 2016, the company operates primarily within the healthcare sector, targeting areas such as oncology, ophthalmology, and metabolic diseases. Lin BioScience maintains a diversified pipeline, which includes advanced drug candidates for the treatment of acute leukemias, solid tumors, glioblastoma, dry age-related macular degeneration, Stargardt disease, non-alcoholic steatohepatitis (NASH), and type 2 diabetes. Its key investigational therapies—such as LBS-007 for acute leukemia and solid tumors, and LBS-008 for retinal diseases—are in various stages of clinical trials, with some programs having received orphan drug and fast track designations from the U.S. FDA. By leveraging internal scientific platforms for metabolic and cancer-related research, the company plays a notable role in advancing first-in-class or best-in-class treatments, positioning itself as a significant contributor to the development of novel therapies within both the Taiwanese and international biopharmaceutical landscapes.